Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

TEVA has been the subject of several other research reports. Barclays decreased their price objective on Teva Pharmaceutical Industries from $38.00 to $23.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. BidaskClub upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. Gabelli restated a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 13th. UBS reaffirmed a “neutral” rating and set a $19.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 14th. Finally, Maxim Group reaffirmed a “hold” rating and set a $15.50 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 14th. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average target price of $21.65.

Shares of Teva Pharmaceutical Industries (TEVA) traded up $0.01 during mid-day trading on Tuesday, reaching $15.06. The company’s stock had a trading volume of 10,220,158 shares, compared to its average volume of 15,647,037. The company has a market capitalization of $15,500.00, a P/E ratio of 3.52 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $38.31.

A number of hedge funds have recently bought and sold shares of the business. Security National Bank of Sioux City Iowa IA lifted its position in shares of Teva Pharmaceutical Industries by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after buying an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the last quarter. CIBC Asset Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 0.3% during the 2nd quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock valued at $2,177,000 after buying an additional 178 shares during the last quarter. Sheaff Brock Investment Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 3.6% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock valued at $279,000 after buying an additional 294 shares during the last quarter. Finally, IFP Advisors Inc lifted its position in shares of Teva Pharmaceutical Industries by 3.8% during the 2nd quarter. IFP Advisors Inc now owns 12,629 shares of the company’s stock valued at $420,000 after buying an additional 459 shares during the last quarter. 52.05% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Rating Increased to Buy at ValuEngine” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-rating-increased-to-buy-at-valuengine/1746237.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.